USRE46424E1 - Method for producing 3-amidinophenylalanine derivatives - Google Patents

Method for producing 3-amidinophenylalanine derivatives Download PDF

Info

Publication number
USRE46424E1
USRE46424E1 US14/145,892 US201314145892A USRE46424E US RE46424 E1 USRE46424 E1 US RE46424E1 US 201314145892 A US201314145892 A US 201314145892A US RE46424 E USRE46424 E US RE46424E
Authority
US
United States
Prior art keywords
derivatives
group
formula
ethoxycarbonyl
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US14/145,892
Inventor
Hugo Ziegler
Peter Wikstroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heidelberg Pharma AG
Original Assignee
Wilex AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/506,256 external-priority patent/US20100284546A1/en
Application filed by Wilex AG filed Critical Wilex AG
Priority to US14/145,892 priority Critical patent/USRE46424E1/en
Application granted granted Critical
Publication of USRE46424E1 publication Critical patent/USRE46424E1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205Radicals derived from carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

The present invention describes a method for the synthesis of enantiomerically pure 3-amidinophenylalanine derivatives, which are used as pharmaceutically effective urokinase inhibitors, by starting from 3-cyanophenylalanine derivatives. The methods of manufacture comprising only one synthesis step lead to new intermediates, namely 3-hydroxyamidino- and 3-amidrazonophenylalanine derivatives. These intermediates or their acetyl derivatives can be reduced into the desired 3-amidino-phenylalanine derivatives under gentle conditions (H2 or ammonium formiate formate, Pd/C (approx. 10%), ethanol/water, room temperature, normal pressure or also H2, Pd/C, AcOH or HCl/ethanol, 1-3 bar) in excellent yields and in an enantiomeric excess of up to 99.9%.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a broadening reissue application for U.S. Pat. No. 8,088,921 B2, which granted from U.S. application Ser. No. 12/905,769, filed Oct. 15, 2010 which is a divisional of U.S. application Ser. No. 11/699,228, filed Jan. 29, 2007, now U.S. Pat. No. 7,884,206, which is a divisional of U.S. application Ser. No. 10/506,256, filed Aug. 30, 2004, and afforded a 371(c) date of Mar. 18, 2005, now U.S. Pat. No. 7,211,670, which U.S. application Ser. No. 10/506,256 is the National Stage of International Application No. PCT/CH03/00147, filed Feb. 28, 2003, which claims the benefit of Swiss Application No. 0347/02, filed Feb. 28, 2002, the entire contents of all of which are incorporated by reference herein.
FIELD OF THE INVENTION
The present invention relates to a method for the synthesis of 3-amidinophenyl-alanine derivatives with an improved total chemical yield and an increased enantiomeric excess. These 3-amidinophenylalanine derivatives represent a class of highly efficient urokinase inhibitors (WO 00/17158).
BACKGROUND OF THE INVENTION
The methods of synthesis described in WO 00/17158 for the preparation of urokinase inhibitors comprise a method for converting the cyano function of substituted 3-cyanophenylalanine derivatives into an amidino function. The disadvantages of the method are the insufficient yield produced by the multi-step transformation of the nitrile function into the amidino function, the use of carcinogenic reagents such as hydrogen sulphide and methyl iodide, as well as the release of methyl mercaptan in the form of a highly toxic gas as a by-product. The method requires a considerable quantity of devices and additional separation processes. Moreover, racemization and thus lower enantiomeric excess must be taken into account.
Transformation of a para-positioned nitrile group into an amidino function with hydroxylamine hydrochloride/triethylamine and subsequent Pd-catalytic hydration (10 bar/AcOH/50° C.) is described in Tetrahedron 51, 12047-68 (1995) (FIG. 3). However, the reaction conditions are so harsh that the chemical yield and the chemical purity are not satisfying. There is no indication about the enantiomeric excess.
In Tetrahedron Letters 40, 7067-71 (1999), a new gentle method for the preparation of aromatic amidines from nitriles is described which should be more advantageous than all other methods known. The reaction is performed with acetylcysteine and ammonia at temperatures of approximately 60° C. The disadvantage of this method lies in the fact that reasonable yields can only be obtained with π electron-poor (=πelectron-attracting) aromates.
Surprisingly, it has been found that transformation of the aromatic 3-cyano function of substituted phenylalanine derivatives of general formula (III) into the 3-amidino function of corresponding compounds of general formula (I) with hydroxylamine and subsequent reduction of the oxyamidine of general formula (IIa) with hydrogen over Pd—C (10%) or reduction of the corresponding acetyloxyamidine manufactured in situ with acetanhydride with ammonium formiate formate over Pd—C (10%) can be managed under gentle reaction conditions (see following FIG. 1). Here, reaction products with a high chemical yield and purity are obtained using only few devices and without racemization.
Moreover, EP 0 739 886 A2 describes a method for the synthesis of 4-amidrazono-phenylalanine derivatives from corresponding nitriles. Here, the nitrile is first converted into the corresponding thioamide which is activated over a thioimidoester derivative in such a way that it reacts with hydrazine to form hydrazonoamide (amidrazone).
A direct transformation of the nitrile group into an amidrazone is described in J. Heterocyclic Chem. 26, 1623 (1989). Here, π electron-deficient heteroaromates substituted with cyano (i.e. cyano groups favourable to a nucleophilic attack) have been heated with hydrazine for some hours, whereby amidrazone was obtained in moderate yields.
Moreover, it has been surprisingly found that also a non-activated nitrile that is not bound to an electron-attracting group can be transformed with hydrazine under similar conditions. Thus, compounds of formula (III) can be transformed into amidrazones of formula (IIb) in good yields (see FIG. 1).
Surprisingly, it has also been found that these amidrazones—analogously to the amidoximes of formula (IIa)—can be reduced to the amidines of formula (I) (see FIG. 1). The direct transformation of an unsubstituted amidrazone into an unsubstituted amidine has until now only been described, namely in the case of aza transfer reactions between arylamidrazones and aryldiazonium salts in Vestn. Slov. Kem. Drus. (1980), 27(3), 251-64.
SUMMARY OF THE INVENTION
Thus, the object of the present invention is a method for transforming 3-cyano-phenylalanine derivatives of general formula (III) into 3-amidino derivatives of general formula I, or salts thereof formed with acids, which are present either as L- or D-configurated compounds and wherein R1 represents (a) a group of formula
Figure USRE046424-20170606-C00001

in which either p=1 and r=2 and R2 is benzyloxycarbonyl, benzylaminocarbonyl or 2-thienylhydrazinocarbonyl, or p=2 and r=1 and R2 is ethoxycarbonyl, 2-propyloxycarbonyl, 2-propylaminocarbonyl, methylaminocarbonyl or methyl; or (b) a group of formula
Figure USRE046424-20170606-C00002

in which R3 is methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, dimethylaminocarbonyl, acetyl or propionyl;
using minimal equipment in high chemical yield and purity as well as without racemization.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows how compounds of formula (III) can be transformed into amidoximes of formula (IIa) and into amidrazones of formula (IIb) and how such amidoximes and amidrazones can be reduced to amidines of formula (I).
DETAILED DESCRIPTION OF THE INVENTION
In a first embodiment of the method of the present invention, transformation of the nitrile group into the amidino function occurs over the amidoxime intermediate of general formula (IIa) by means of hydroxylamine hydrochloride in the presence of sodium carbonate in alcoholic-aqueous solution at reflux temperature, advantageously by boiling for 2 to 20 hours, preferably 4 to 10 hours, a compound of formula (III) with a one to 5-fold excess of hydroxylamine hydrochloride/0.5-0.6 equiv. sodium carbonate in an alcoholic-aqueous, preferably ethanolic-aqueous solution. However, the transformation of nitrile (III) with hydroxylamine hydrochloride can also occur at room temperature in the presence of triethylamine in alcoholic solution, with or without addition of a further organic solvent, such as methylene chloride.
Subsequent reduction of the amidoxime function is performed either with hydrogen gas or with ammonium formiate formate (which is advantageously applied in an at least 4-fold excess) either by directly starting from unsubstituted amidoxime, or over the acetylated amidoxime manufactured in situ with acetanhydride in the presence of hydrochloric acid, advantageously at 20 to 60° C., in an alcoholic-aqueous solution, preferably in an ethanolic-aqueous solution, advantageously in the ratio of 1:1 to 20:1, preferably 3:1 to 10:1, ideally 5:1, in the presence of Pd/C, advantageously 1 to 50%, preferably 5 to 30% Pd/C (approx. 10%), advantageously at normal pressure and a temperature between 10 and 50° C., preferably between 20 and 30° C., ideally at room temperature. However, reduction can also occur by hydrogenation in the presence of Pd/C in an alcoholic, acetic acid-containing solution at a pressure of about 1-3 bar.
In a second embodiment of the method of the present invention, transformation of 3-cyanophenylalanine derivatives of general formula (III) into 3-amidinoderivatives of general formula I occurs over the amidrazone intermediate of general formula (IIb) by boiling, advantageously for 2 to 20 hours, preferably for 4 to 10 hours, a compound of formula (III) with an excess of hydrazine in alcoholic, preferably ethanolic solution. Reduction of the amidrazone intermediate (IIb) into the corresponding amidine (I) occurs under the same conditions as those starting from amidoxime (IIa).
Further objects of the present invention are compounds of general formula (II) as represented in FIG. 1, in particular those of the following formulas (IV) and (V)
Figure USRE046424-20170606-C00003

as (L)- or (D)-enantiomers, and as (E)- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof formed with acids.
The following examples further explain the improved methods of synthesis of the present invention and the synthesis of new intermediates, however without restricting the invention.
Analysis of the eluates and products obtained according to the examples was carried out with 1H-NMR, HPLC electrospray MS or elementary analysis. The enantiomeric excess was determined according to known methods using HPLC and chiral analytical columns. The starting compounds of general formula (III) and their manufacture are known (e.g. WO 00/17158).
EXAMPLES Example 1 (A) N-α-2,4,6-Triisopropylphenylsulfonyl-3-oxamidino-(L)-phenylalanine-4-ethoxycar-bonyl piperazide
75.4 g (0.126 mol) of N-α-2,4,6-triisopropylphenylsulfonyl-3-cyano-(L)-phenylalanine-4-ethoxycarbonyl piperazide was dissolved in 1.5 l of ethanol, the solution was mixed with 32.5 g (0.47 mol) of hydroxylamine hydrochloride and with a solution of 25.4 g (0.24 mol) of Na2CO3 in 0.5 l of water and refluxed for 6 hours (80° C.). The crude product obtained after evaporation of the solvent was taken up in 1.5 l of ethyl acetate and extracted with water (3×0.5 l), washed with saturated NaCl, dried over Na2SO4, filtered and the solvent was evaporated. Yield: 71.3 g (90%).
(B) N-α-2,4,6-Triisopropylphenylsulfonyl-1-3-amidino-(L)-phenylalanine-4-ethoxycar-bonyl piperazide hydrochloride
71.3 g (0.113 mol) of the N-α-2,4,6-triisopropylphenylsulfonyl-3-oxamidino-(L)-phenylalanine-4-ethoxycarbonyl piperazide obtained under (A) was dissolved in 0.71 l of ethanol and the solution was mixed with a suspension of 14.2 g of 10% palladium coal in 140 ml of water. Injection of hydrogen until saturation was followed by hydration until complete transformation at normal pressure (approx. 5 hours). The suspension was filtered over Celite, washed with ethanol/water (9:1) and the solvent was evaporated. The crude product obtained was purified over silica gel 60 (ethyl acetate/2-propanol, 8:2) and finally transformed into the corresponding hydrochloride over Amberlite IRA-400 (Clform) in 2-propanol/water (8:2). Yield: 65.4 g (89%), ee-value: 99.9% of the (L) form.
(C) N-α-2,4,6-Triisopropylphenylsulfonyl-1-3-amidino-(L)-phenylalanine-4-ethoxycarbonyl piperazide hydrochloride
71.3 g (0.113 mol) of the N-α-2,4,6-triisopropylphenylsulfonyl-3-oxamidino-(L)-phenylalanine-4-ethoxycarbonyl piperazide was dissolved in 0.71 l of ethanol, the solution was mixed with 45.6 g (0.46 mol) of acetic anhydride and stirred for 10 min. at room temperature. Afterwards, 0.46 l of 1 N HCl was added and the thereby warm becoming solution was further stirred for 10 min. After cooling to room temperature, 29 g (0.46 mol) of ammonium formiate formate was added and the mixture was stirred for 5 min. After addition of a suspension of 14.2 g of 10% Pd/C in 140 ml of water, the mixture was stirred for 24 hours at room temperature. After HPLC check of the reaction completion, the suspension was filtered over Celite, washed with a 1:9 mixture of water/ethanol and the solvent was evaporated. The crude product was taken up in 1.5 l of EtOAc, washed with 3 portions of 0.5 l each of 1N HCl, water and saturated NaCl, and dried over Na2SO4. After chromatographic purification over silica gel 60 with ethylacetate/2-propanol (8:2) and subsequent ion exchange chromatography over Amberlite IRA-400 (Clform) in 2-propanol/water (8:2) for the conversion into the corresponding hydrochloride, 62.5 g (85%) of product was obtained. ee value: 99.9% of the (L) form.
Example 2 (A) N-α-2,4,6-Triisopropylphenylsulfonyl-(L)-3-oxamidino-phenylalanyl-nipecotinic acid benzylamide
2.3 g (3.6 mmol) of Nα-2,4,6-triisopropylphenylsulfonyl-(L)-3-cyanophenylalanyl-nipecotinic acid benzylamide was dissolved in 45 ml of ethanol and the solution was mixed with 0.94 g (13.6 mmol) of hydroxylamine hydrochloride followed by a solution of 0.74 g (7 mmol) of Na2CO3 in 15 ml of water and refluxed for 6 hours (80° C.). The crude product obtained after evaporation of the solvent was taken up in 100 ml of ethylacetate, extracted with water (3×30 ml), washed with saturated NaCl, dried over Na2SO4 and filtered, and the solvent was evaporated. Yield: 2.1 g (87%).
(B) N-α-2,4,6-Triisopropylphenylsulfonyl-(L)-3-amidino-phenylalanyl-nipecotinic acid benzylamide hydrochloride
2.1 g (3.1 mmol) of the N-α-2,4,6-triisopropylphenylsulfonyl-(L)-3-oxamidino-phenylalanyl-nipecotinic acid benzylamide obtained under (A) was dissolved in 20 ml of ethanol and the solution was mixed with a suspension of 0.4 g of 10% palladium coal in 5 ml of water. Injection of hydrogen until saturation was followed by hydration at normal pressure until complete transformation (approx. 4 hours). The suspension was filtered over Celite, washed with ethanol/water (9:1) and the solvent was evaporated. The crude product obtained was purified over silica gel 60 (ethylacetate/2-propanol, 8:2) and finally converted into the corresponding hydrochloride over Amberlite IRA-400 (Clform) in 2-propanol/water (8:2). Yield: 1.74 g (85%), ee value: 99.7% of the (L) form.
Example 3 (A) N-α-2,4,6-Triisopropylphenylsulfonyl-3-amidrazono-(L)-phenylalanine-4-ethoxy-carbonyl piperazide
75.4 g (0.126 mol) of N-α-2,4,6-triisopropylphenylsulfonyl-3-cyano-(L)-phenylalanine-4-ethoxycarbonyl piperazide was dissolved in 1.5 l of ethanol, the solution was mixed with 18.1 g (0.47 mol) of a 100% hydrazine hydrate solution and refluxed for 6 hours (80° C.). The crude product obtained after evaporation of the solvent was taken up in 1.5 l of ethylacetate, extracted with water (3×0.5 l), washed with saturated NaCl, dried over Na2SO4 and filtered, and the solvent was evaporated. Yield: 65.7 g (83%).
B) N-α-2,4,6-Triisopropylphenylsulfonyl-3-amidino-(L)-phenylalanine-4-ethoxycarbonyl piperazide hydrochloride
65.5 g (0.104 mol) of the N-α-2,4,6-triisopropylphenylsulfonyl-3-amidrazono-(L)-phenylalanine-4-ethoxycarbonyl piperazide obtained under (A) was dissolved in 0.66 l of ethanol and the solution was mixed with a suspension of 13.1 g of 10% palladium coal in 130 ml of water. Injection of hydrogen gas until saturation was followed by hydration at normal pressure until complete transformation (approx. 5 hours). The suspension was filtered over Celite and washed with ethanol/water (9:1), and the solvent was evaporated. The crude product obtained was purified over silica gel 60 (ethylacetate/2-propanol, 8:2) and finally converted into the corresponding hydrochloride over Amberlite IRA-400 (Clform) in 2-propanol/water (8:2). Yield: 54.1 g (80%), ee value: 99.8% of the (L) form.

Claims (9)

What is claimed is:
1. A method of synthesizing 3-amidino-phenylalanine derivatives of general formula (I)
Figure USRE046424-20170606-C00004
or salts thereof formed with acids, which are present as either L- or D-configurated isomers and wherein R1 is selected from the group consisting of:
(a) a group of formula
Figure USRE046424-20170606-C00005
wherein
(i) p=1 and r=2 and R2 is benzyloxycarbonyl, benyzlaminocarbonyl benzylaminocarbonyl or 2-thienylhydrazinocarbonyl or
(ii) p=2 and r=1 and R2 is ethoxycarbonyl, 2-propyloxycarbonyl, 2-propylcarbonyl, 2-propylaminocarbonyl, methylaminocarbonyl or methyl; and
(b) a group of formula
Figure USRE046424-20170606-C00006
wherein R3 is selected from the group consisting of methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, dimethylaminocarbonyl, acetyl, and propionyl,
comprising the reduction of a compound of the general formula (IIa)
Figure USRE046424-20170606-C00007
present as L- or D-enantiomers, as (E)- or (Z)-isomers or (E/Z)-mixtures, and wherein R1 is selected from the group consisting of:
(a) a group of formula
Figure USRE046424-20170606-C00008
wherein
(i) p=1 and r=2 and R2 is benzyloxycarbonyl, benyzlaminocarbonyl benzylaminocarbonyl or 2-thienylhydrazinocarbonyl or
(ii) p=2 and r=1 and R2 is ethoxycarbonyl, 2-propyloxycarbonyl, 2-propylcarbonyl, 2-propylaminocarbonyl, methylaminocarbonyl or methyl; and
(b) a group of formula
Figure USRE046424-20170606-C00009
wherein R3 is selected from the group consisting of methoxycarbonyk methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, dimethylaminocarbonyl, acetyl, and propionyl,
in the presence of Pd/C in an alcoholic-aqueous solution with hydrogen or ammonium formiate formate.
2. The method of claim 1, wherein the compound of the general formula (IIa) is hydrogenated in the presence of Pd/C in an alcoholic, acetic acid- or hydrogen chloride-containing solution at a pressure of 1-3 bar.
3. The method of claim 1, further comprising the step of transforming the compounds of general formula (IIa) into the corresponding acetoxyamidino derivatives with acetanhydride in the presence of hydrochloric acid and reducing the derivatives with hydrogen or ammonium formiate in the presence of Pd/C in an alcoholic-aqueous solution.
4. The method of claim 3 1, wherein the acetoxyamidino derivatives are hydrogenated in the presence of Pd/C in an alcoholic, acetic acid- or hydrogen chloride-containing solution at a pressure of 1-3 bar.
5. The method of claim 3 1, wherein the transformation of the compounds of formula (IIa) into the corresponding acetoxyamidino derivatives occurs at a temperature between 20 and 60° C.
6. The method of claim 1, wherein the reduction occurs in an ethanolic-aqueous solution having a ratio of 1:1 to 20:1.
7. The method of claim 1, wherein the reduction occurs in the presence of 1 to 50% Pd/C.
8. The method of claim 1, wherein the reduction occurs at a temperature of 10 to 50° C.
9. The method of claim 1, wherein the reduction occurs with an at least 4-fold excess of ammonium formiate formate.
US14/145,892 2002-02-28 2013-12-31 Method for producing 3-amidinophenylalanine derivatives Expired - Fee Related USRE46424E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/145,892 USRE46424E1 (en) 2002-02-28 2013-12-31 Method for producing 3-amidinophenylalanine derivatives

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CH00347/02A CH695999A5 (en) 2002-02-28 2002-02-28 A process for preparing 3-amidinophenylalanine derivatives.
CH0347/02 2002-02-28
PCT/CH2003/000147 WO2003072559A1 (en) 2002-02-28 2003-02-28 Method for producing 3-amidinophenylalanine derivatives
US11/506,256 US20100284546A1 (en) 2005-08-18 2006-08-18 Active noise control algorithm that requires no secondary path identification based on the SPR property
US11/699,228 US7884206B2 (en) 2002-02-28 2007-01-29 Method for producing 3-amidinophenylalanine derivatives
US12/905,769 US8088921B2 (en) 2002-02-28 2010-10-15 Method for producing 3-amidinophenylalanine derivatives
US14/145,892 USRE46424E1 (en) 2002-02-28 2013-12-31 Method for producing 3-amidinophenylalanine derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/905,769 Reissue US8088921B2 (en) 2002-02-28 2010-10-15 Method for producing 3-amidinophenylalanine derivatives

Publications (1)

Publication Number Publication Date
USRE46424E1 true USRE46424E1 (en) 2017-06-06

Family

ID=27762105

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/506,256 Expired - Lifetime US7211670B2 (en) 2002-02-28 2003-02-28 Method for producing 3-amidinophenylalanine derivatives
US11/699,228 Active 2025-09-13 US7884206B2 (en) 2002-02-28 2007-01-29 Method for producing 3-amidinophenylalanine derivatives
US12/905,769 Ceased US8088921B2 (en) 2002-02-28 2010-10-15 Method for producing 3-amidinophenylalanine derivatives
US13/300,237 Expired - Lifetime US8642761B2 (en) 2002-02-28 2011-11-18 Method for producing 3-amidinophenylalanine derivatives
US14/145,892 Expired - Fee Related USRE46424E1 (en) 2002-02-28 2013-12-31 Method for producing 3-amidinophenylalanine derivatives

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US10/506,256 Expired - Lifetime US7211670B2 (en) 2002-02-28 2003-02-28 Method for producing 3-amidinophenylalanine derivatives
US11/699,228 Active 2025-09-13 US7884206B2 (en) 2002-02-28 2007-01-29 Method for producing 3-amidinophenylalanine derivatives
US12/905,769 Ceased US8088921B2 (en) 2002-02-28 2010-10-15 Method for producing 3-amidinophenylalanine derivatives
US13/300,237 Expired - Lifetime US8642761B2 (en) 2002-02-28 2011-11-18 Method for producing 3-amidinophenylalanine derivatives

Country Status (12)

Country Link
US (5) US7211670B2 (en)
EP (1) EP1480963B1 (en)
JP (2) JP5247970B2 (en)
CN (1) CN100369906C (en)
AT (1) ATE361285T1 (en)
AU (1) AU2003205498A1 (en)
CH (1) CH695999A5 (en)
DE (1) DE50307171D1 (en)
DK (1) DK1480963T3 (en)
ES (1) ES2282601T3 (en)
PT (1) PT1480963E (en)
WO (1) WO2003072559A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11045453B1 (en) 2020-03-10 2021-06-29 Redhill Biopharma Ltd. Serine protease inhibitor for treating coronavirus infection
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695999A5 (en) * 2002-02-28 2006-11-15 Wilex Ag A process for preparing 3-amidinophenylalanine derivatives.
DE10323898A1 (en) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
CA2583771C (en) * 2004-10-14 2013-08-27 Wilex Ag Method for cleaning 3-hydroxyamidinophenylalanine derivatives by the precipitation and recrystallization of salt and an aromatic sulfonic acid
DE102004057195A1 (en) * 2004-11-26 2006-06-01 Wilex Ag Crystalline modifications of N-alpha (2,4,6-triisopropylphenylsulfonyl) -3-hydroxyamidino- (L) -phenylalanine-4-ethoxycarbonylpiperazide and / or salts thereof
EP2832724A4 (en) * 2012-03-29 2015-09-23 Toray Industries Nipecotic acid derivative and use thereof for medical purposes
CN114105910B (en) * 2021-11-02 2024-04-12 北京悦康科创医药科技股份有限公司 Hydroxycarbamimidoyl phenylalanine derivative, pharmaceutical composition and application

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2375611A (en) * 1941-08-19 1945-05-08 May & Baker Ltd Production of amidines
US5518735A (en) * 1990-11-15 1996-05-21 Pentapharm Ag Meta-substituted phenylalanine derivatives
EP0739886A2 (en) 1995-04-28 1996-10-30 LG Chemical Limited Selective thrombin inhibitors
JPH10509727A (en) 1994-12-06 1998-09-22 ビーエーエスエフ アクチェンゲゼルシャフト Novel dipeptide p-aminobenzylamides having an N-terminal sulfonyl- or aminosulfonyl group
WO1998054132A1 (en) 1997-05-30 1998-12-03 Daiichi Pharmaceutical Co., Ltd. Process for preparing 3-(7-amidino-2-naphthyl)-2-phenylpropionic acid derivatives
CH689611A5 (en) 1995-03-01 1999-07-15 Pentapharm Ag New amidino-phenylalanine derivatives
WO2000017158A1 (en) 1998-09-18 2000-03-30 Pentapharm Ag Urokinase inhibitors
WO2001053280A1 (en) 2000-01-21 2001-07-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted phenylamidines medicaments containing said compounds and method for production thereof
WO2001055175A2 (en) 2000-01-28 2001-08-02 Aventis Pharma Deutschland Gmbh Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695999A5 (en) * 2002-02-28 2006-11-15 Wilex Ag A process for preparing 3-amidinophenylalanine derivatives.

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2375611A (en) * 1941-08-19 1945-05-08 May & Baker Ltd Production of amidines
US5518735A (en) * 1990-11-15 1996-05-21 Pentapharm Ag Meta-substituted phenylalanine derivatives
US5852051A (en) 1994-12-06 1998-12-22 Basf Aktiengesellschaft Dipeptide p-amidinobenzylamides with N-terminal sulfonyl or aminosulfonyl radicals
JPH10509727A (en) 1994-12-06 1998-09-22 ビーエーエスエフ アクチェンゲゼルシャフト Novel dipeptide p-aminobenzylamides having an N-terminal sulfonyl- or aminosulfonyl group
CH689611A5 (en) 1995-03-01 1999-07-15 Pentapharm Ag New amidino-phenylalanine derivatives
EP0739886A2 (en) 1995-04-28 1996-10-30 LG Chemical Limited Selective thrombin inhibitors
WO1998054132A1 (en) 1997-05-30 1998-12-03 Daiichi Pharmaceutical Co., Ltd. Process for preparing 3-(7-amidino-2-naphthyl)-2-phenylpropionic acid derivatives
US6342609B2 (en) 1997-05-30 2002-01-29 Daiichi Pharmaceutical Co., Ltd. Process for preparing 3-(7-amidino-2-naphthyl)-2-phenylpropionic acid derivatives
WO2000017158A1 (en) 1998-09-18 2000-03-30 Pentapharm Ag Urokinase inhibitors
US7745441B1 (en) * 1998-09-18 2010-06-29 Wilex Ag Urokinase inhibitors
WO2001053280A1 (en) 2000-01-21 2001-07-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted phenylamidines medicaments containing said compounds and method for production thereof
US6838460B2 (en) 2000-01-21 2005-01-04 Boehringer Ingelheim Pharma Kg Substituted phenylamidines medicaments containing said compounds and method for production thereof
WO2001055175A2 (en) 2000-01-28 2001-08-02 Aventis Pharma Deutschland Gmbh Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Protecting Group", on-line publication, Wikipedia, http://en.wikipedia.org/wiki/Protecting-group, (May 2, 2006).
"Protecting Group", on-line publication, Wikipedia, http://en.wikipedia.org/wiki/Protecting—group, (May 2, 2006).
English translation of Japanese Office Action for Application No. 2003-571265 dated Jun. 2, 2009.
English translation of Japanese Office Action for Patent Application No. 2003-571265 dated Jun. 2, 2009.
International Search Report for PCT/CH03/00147 mailed on Jun. 20, 2003.
Jendralla, H., et al., "Efficient Kg-Scale Synthesis of Thrombin Inhibitor CRC 220", Tetrahedron, vol. 51, No. 44, pp. 12047-12068 (1995).
Judkins, B.D. et al., "A Versatile Synthesis of Amidines from Nitriles via Amidoximes", Synthetic Communications, 26 (23), pp. 4351-4367 (1996).
Lange, U. et al., "A New Mild Method for the Synthesis of Amidines", Tetrahedron Letters, 40, pp. 7067-7070 (1999).
Monge, A., et al., "New Quinoxaline and Pyrimido[4,5-b]quinoxaline Derivatives. Potential Antihypertensive and Blood Platelet Antiaggregating Agents", J. Heterocyclic Chem., 26, pp. 1623-1626 (Nov.-Dec. 1989).
Smith, M. B., "Organic Synthesis", pp. 658-664.
Stanovnik, B., et al., "AZA-Transfer Reactions The Reaction Between Aroyl and Heteroylhydrazines and Aryldiazonium Compounds", Vestn. Slov. Kem. Drus. 27(3), pp. 251-264 (1980).
Stürzbecher, J., et al., "3-Amidinophylalanine-based Inhibitors of Urokinase", Bioorganic & Medicinal Chemistry Letters, 9, pp. 3147-3152 (1999).
Stürzebecher et al., Bioorganic & Medicinal Chemistry Letters, (1999), vol. 9, p. 3147-3152 (disclosed in the IDS). *
Translation of Russian Chemical Bulletin, 51(11), 2100-2105, (2002).

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11045453B1 (en) 2020-03-10 2021-06-29 Redhill Biopharma Ltd. Serine protease inhibitor for treating coronavirus infection
US11052073B1 (en) 2020-03-10 2021-07-06 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection
US11364227B2 (en) 2020-03-10 2022-06-21 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection
US11918560B2 (en) 2020-03-10 2024-03-05 Redhill Biopharma Ltd. Serine protease inhibitor for treating coronavirus infection
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia

Also Published As

Publication number Publication date
ES2282601T3 (en) 2007-10-16
US20110087025A1 (en) 2011-04-14
WO2003072559A1 (en) 2003-09-04
DK1480963T3 (en) 2007-09-10
ATE361285T1 (en) 2007-05-15
CH695999A5 (en) 2006-11-15
EP1480963A1 (en) 2004-12-01
CN1639142A (en) 2005-07-13
US8088921B2 (en) 2012-01-03
DE50307171D1 (en) 2007-06-14
JP2010265288A (en) 2010-11-25
US7884206B2 (en) 2011-02-08
AU2003205498A1 (en) 2003-09-09
JP2005532270A (en) 2005-10-27
US20050176962A1 (en) 2005-08-11
CN100369906C (en) 2008-02-20
US20070123706A1 (en) 2007-05-31
US7211670B2 (en) 2007-05-01
EP1480963B1 (en) 2007-05-02
PT1480963E (en) 2007-05-31
US8642761B2 (en) 2014-02-04
US20120065398A1 (en) 2012-03-15
JP5247970B2 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
USRE46424E1 (en) Method for producing 3-amidinophenylalanine derivatives
EA015801B1 (en) Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates
WO2015104721A2 (en) An improved process for the preparation of tranexamic acid
US8030491B2 (en) Process and intermediate for preparation of donepezil
WO2007108011A2 (en) Process for the preparation of highly pure donepezil
EP1867635A1 (en) Process for preparing remifentanil, intermediates thereof, use of said intermediates and processes for their preparation
JP2002524550A (en) Method for producing N-substituted hydroxycycloalkylamine derivative
US10844014B2 (en) Intermediates for the preparation of remifentanil hydrochloride
HU231050B1 (en) Process for the preparation of a pharmaceutical active ingredient
KR100914691B1 (en) Process for preparing donepezil or its synthetic intermediate
EP2234975B1 (en) Process for producing pipecolic-2-acid-2 ',6'-xylidide useful as an intermediate for the preparation of local anesthetics
KR100374405B1 (en) A new process for amlodipine besylate
CN111247127B (en) Process for the production of intermediate compounds for the synthesis of medicaments
CN115819251B (en) Preparation method of (1R) -1- [3- (difluoromethyl) -2-fluorophenyl ] ethylamine
CN101180289A (en) Method for the production of substituted 2-alkoxycarbonyl-3-aminothiophenes
US20040176412A1 (en) Process for the preparation of threo-methylphenidate hydrochloride
AU744361B2 (en) Method for producing a 1-(3-cyclopentenyloxy- 4-alkoxyphenyl)-4- oxocyclohexanecarbonitrile
JP3202120B2 (en) 1,4-dihydropyridine derivative and method for producing 1,4-dihydropyridinecarboxylic acid derivative using the same
US6313315B1 (en) Methods for producing N-protected-azetidine-2-carboxylic acids
US20110112309A1 (en) Preparation process useful in synthesis of atorvastatin
CA2201779C (en) The manufacture of levobupivacaine and analogues thereof from l-lysine
JP4441260B2 (en) Process for producing 4-amino-4-phenylpiperidines
US6506907B1 (en) Process
WO2019098551A1 (en) Method for preparing intermediate compound for synthesizing pharmaceutical
KR20050122481A (en) Novel intermediate compound for amlodipine besylate and preparation process of amlodipine besylate using thereof

Legal Events

Date Code Title Description
MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY